HeR2 positive breast cancer.
In the case of HeR2-positive breast cancer patients, endocrine treatment has some therapeutic effect if the cancer cell expresses both estrogen receptor (ER) or pregnancy hormone receptor (PR). 1. Activation mechanisms • Endocrine treatment drugs inhibit the growth of cancer cells by regulating the hormonal levels in the body and by interfering with the combination of hormones and cancer cell receptors. For example, he moxiphine can compete with estrogen receptors to prevent estrogen from stimulating growth of cancer cells. • Aromatic enzyme inhibitors (e.g., aromatic aroma, anacara, etc.) reduce the synthesis of estrogens in the body by inhibiting the activity of aromatic enzymes, thus reducing the risk of re-emergence of tumors by making cancer cell growth less irritant by estrogens. 2. Clinical data • For eligible HeR2-positive breast cancer patients, there has been a degree of improvement in their five-year disease-free survival after the completion of the HeR2 treatment and chemotherapy treatment. 1. Assistive treatment as part of the overall treatment programme, endocrine treatment can prolong the patient’s life. Especially for hormonal receptor-positive, HeR2-positive and at an early stage of the disease, the synergy of endocrinological treatment with other treatments (e.g. target-based treatment, chemotherapy, etc.) helps to control the progress of tumours and prolongs the life of patients. In the case of late-stage HeR2-positive breast cancer patients, endocrinological treatment can also alleviate symptoms and stabilize conditions to a certain extent if hormonal receptor-positive, thereby increasing the duration of life of the patient and improving the quality of life. Endocrine treatment has the following effects on the quality of life of persons with positive breast cancer in Her2: When endocrine treatment is effective in inhibiting the growth of tumours and reducing the risk of relapse, the patient is able to reduce psychological stress by controlling the condition. For example, patients do not always have to fear the recurrence or transfer of tumours, and psychological anxiety and fear decrease, which has a positive impact on the overall quality of life. 2. Hopes for long-term survival • Endocrine treatment has been extended to some extent, allowing patients more time to spend with their families and participate in social activities. Patients can plan their own lives, such as continuing to work, travelling, etc., and maintain a positive attitude towards life. • Thermal red: this is a common side effect of endocrine treatment. Patients suddenly feel hot and red on their faces, necks and chests, possibly accompanied by sweat, which seriously affects their comfort, especially in social settings. • Artificial pain: Some patients suffer from joint pain, which affects their daily mobility, such as walking, up and down the stairs, which limits the scope of their activities and reduces the ease of life. • Increased risk of osteoporosis: Endocrine treatments such as aromatic enzyme inhibitors can lead to loss of bone and increase the risk of osteoporosis. The potential for bone pain and the vulnerability of patients to fractures severely limit their freedom of movement and require additional attention to the prevention and treatment of osteoporosis. Sexual function disorders: Some endocrine treatment drugs may affect the sexual function of the patient, including sexual depreciation, pain in sexual intercourse, etc., and have a negative impact on the relationship and the quality of sexual life of the patient.
